Xoma presents positive interim data from Phase I studies of diabetes drug
Xoma 052 demonstrated biological activity in patients with type 2 diabetes as measured by diabetes and inflammatory markers. The interim analysis of two single-dose, dose-escalation, Phase I studies
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.